Safety Profile, Contraindications and Regulation
Electrochemotherapy is a local treatment, and the published frameworks give its single-session drug doses as numbers (15,000 IU/m² for intravenous bleomycin). , How that bears on the safety profile is not stated here as a generalisation but transcribed row by row in the tables below: they report events as described in the literature and the contraindication headings of the published frameworks, and every row carries its source.
Clinical Reference. This section is independent of the portal's publication counting: the values here are not computed from the corpus but taken from the named procedure, guidance and manufacturer documents, each shown with its source. When the source document is revised, this page changes with it. If you spot an error on this page, write to info@dgmed.com.tr. The portal publishes no clinical review record (reviewer and date) for this page; the content is transcribed from the source documents named above, and what binds are the current versions of those documents.
Adverse Events Reported in the Literature: Electrochemotherapy
| Reported event | Reported mechanism or context | Management in the published framework | Source |
|---|---|---|---|
| Muscle contraction during delivery | Direct stimulation of muscle and nerve by the pulses; a frequency of 5,000 Hz reduces the number of contractions but makes the single contraction more forceful | Anaesthesia plan; choice of frequency; lifting the treatment area with a gauze pad | , , |
| Post-procedural pain | Tissue stimulation and post-procedural inflammation; pre-treatment pain score, previously irradiated fields and large tumours are reported as risk markers | A pain management plan set at the pre-treatment visit | , |
| Erythema, oedema and superficial necrosis | Response of the treated tissue | Wound care. Healing may take up to 10 weeks for lesions over 1.5 cm and 4–8 weeks for smaller ones. | |
| Hyperpigmentation | Reported after intravenous bleomycin in skin where pressure has been exerted: needle electrode marks, removal of ECG electrodes, drapes and pressure from the operating table | Attention to patient positioning; gentle removal of drapes and tags; discussing the cosmetic outcome beforehand | |
| Delayed healing in irradiated fields | Fibrosis in tissue that has previously received radiotherapy | Local anaesthesia is also reported to be more difficult in these fields and to need longer diffusion time | |
| Neurological complications in the head and neck area | Proximity of the treatment site to nerve structures | Addressed separately in a region-specific study; anatomical assessment before treatment | |
| Cardiac events | Pulses coinciding with the vulnerable cardiac period | ECG synchronisation for applications near the heart. Where the tissue to be treated lies close to the heart or to the pacemaker, treatment is considered contraindicated in patients with an implanted pacemaker. | , |
| Bleomycin-related pulmonary toxicity | Lifetime cumulative bleomycin dose | The lifetime cumulative dose is capped; the numeric thresholds and monitoring criteria are given in the Bleomycin and Cumulative Dose section below. | , |
This table is not an exhaustive list of adverse events. It is selective: it transcribes only those events that the published frameworks cited above, and the related studies in the corpus, treat under a heading of their own. Events not given such a heading in those frameworks (site infection or bleeding from an ulcerated lesion, for example) do not appear here as rows, and their absence does not mean they have not been reported. For a complete and current list of adverse effects, consult the summary of product characteristics for the drug used and the device’s instructions for use. Some local reactions are part of the treatment response and are described as the expected course rather than complications. For cohort-level safety and efficacy reporting, see the prospective registry studies.
Contraindication and Caution Headings in the Published Frameworks
| Condition | What the published framework says | Source |
|---|---|---|
| Known allergy or hypersensitivity to the agent used | The 2006 procedure permits bleomycin only where there is no history of allergy and asks whether cisplatin can be substituted where there is; the 2018 update lists this under contraindications. | , |
| Lifetime cumulative bleomycin dose | The 2006 procedure requires that the 400,000 IU/m² limit has not been reached; the 2018 update states that the lifetime dose should not exceed 400,000 IU. | , |
| Renal function | Creatinine < 150 µmol/L is required for intravenous bleomycin; in low clearance a reduced dose is considered according to institutional guidance. | |
| Pulmonary status | A pre-treatment lung diffusion capacity test is recommended in symptomatic pulmonary disease; in benign indications the test is done before and after treatment. | |
| Pregnancy and lactation | The 2018 update lists this under contraindications and requires adequate contraception in potentially fertile patients. | |
| Patient with a pacemaker or ICD | The 2006 procedure describes excluding nodules on the anterior chest wall while nodules elsewhere remain treatable. Where the tissue to be treated lies close to the heart or the device, treatment is considered contraindicated. | , |
| Coagulation disorder | The 2006 procedure describes switching from needle electrodes to plate (type I) electrodes; patients whose nodules are all deep are not considered eligible under this condition. |
This table is not a contraindication list but a transcription of the relevant headings of the published procedure documents, and it carries no grading. What binds is the current summary of product characteristics for the drug in your country, the device’s current instructions for use and your institution’s approved protocol.
Bleomycin and Cumulative Dose
The most serious dose-dependent toxicity of bleomycin is pulmonary fibrosis, and risk rises with lifetime cumulative dose. The 2006 procedure states that the lifetime dose should not exceed 400,000 IU/m² and that pulmonary function tests should be considered once the cumulative dose passes 60,000 IU/m². The 2018 update gives the lifetime limit as 400,000 IU and advises discontinuation if lung diffusion capacity falls by more than 25% from baseline.
The published frameworks give the bleomycin dose delivered in a single session as a number (15,000 IU/m² by the intravenous route, capped at a total of 30,000 IU in the 2018 update) and tie the upper limit not to the single-session dose but to the lifetime cumulative dose. , Repeated sessions and the patient’s prior bleomycin exposure are therefore assessed together. Tracking and recording the cumulative dose is something the frameworks leave to the treating side: the eligibility checklist asks that the amount of previous bleomycin delivery be known. How that information is kept follows the treating institution’s protocol, and the portal defines no requirement on the matter.
Regulatory Framework
| Document | Scope | Its nature and what it says | Source |
|---|---|---|---|
| NICE HTG305 (United Kingdom; published in 2013 as IPG446) | Metastases in the skin from tumours of non-skin origin, and melanoma | States that in the context of palliative treatment the procedure may be used with normal arrangements for clinical governance, consent and audit. | nice.org.uk/guidance/htg305 |
| NICE HTG333 (United Kingdom; published in 2014 as IPG478) | Primary basal cell and squamous cell carcinoma | States that evidence on efficacy is limited in quantity and quality; requires special arrangements for clinical governance, consent and local audit, and submission of data to a register. | nice.org.uk/guidance/htg333 |
| ESOPE standard operating procedures (2006; updated 2018) | 2006: cutaneous and subcutaneous tumour nodules. The 2018 update: cutaneous tumours and skin metastases; internal-organ tumours are outside its scope. | A European multicentre consensus document; a practice standard, not binding regulation. | , |
| National regulations | Vary by country | Device approval status, off-label drug use and reimbursement conditions are separate processes and are not assessed on this page. | no source cited |
The NICE guidance was published in 2013 and 2014 as IPG446 and IPG478 and was later moved, with content unchanged, to the HealthTech guidance numbering: IPG446 → HTG305, IPG478 → HTG333. The old numbers are historical. This table covers only the documents named above; the regulatory position in other countries has not been surveyed.
The full set of regulatory documents in the archive (FDA 510(k) clearances, health technology assessments, trial registration records and manufacturer manuals) is listed on Clearance and Assessment Documents. The table here interprets those of them that bear directly on electrochemotherapy.
Safety in Irreversible Electroporation (IRE)
High-voltage pulses cause severe muscle contraction; published applications were performed under general anaesthesia with complete muscle relaxation, and a deeper neuromuscular blockade is reported to be needed for retroperitoneal sites. , ECG synchronisation is used to keep pulses out of the vulnerable cardiac period; in patients with a pacemaker, treatment is considered contraindicated where the tissue to be treated lies close to the heart or the device.
For deep organ applications, electrodes are placed under imaging guidance, which brings procedure-specific risks along the needle tract. That the method’s non-thermal nature lets critical structures of the tissue matrix, such as vessels, be spared is given as the reason IRE is investigated in locations adjacent to them ; that sparing is not absolute. The corpus includes a real-world safety analysis of reports submitted to a regulatory adverse event database for a commercial IRE system.